Summary: Unglycosylated recombinant human a1-acid glycoprotein (hAGP) variants (rF1*S and rA) were prepared in an E. coli expression system using the Origami B strain and pET-3c vector. Thioredoxin was coexpressed to promote the appropriate folding of hAGP. SDS-PAGE under reducing conditions showed that rF1 * S and rA migrate as single bands after purification. However, several bands derived from rA were observed under non-reducing conditions because of the high reactivity of a free cystein residue (C149). We therefore prepared a mutant of A variant (C149R-A), and confirmed that this mutant maintained homogeneity. Circular dichroism and intrinsic tryptophan fluorescence spectroscopic analyses indicated that rF1 * S and C149R-A have almost the same conformational structures as F1*S and A purified from serum. Ligand binding experiments using propranolol as a F1 * S ligand and disopyramide as an A specific ligand indicated that the capacity of rF1*S and C149R-A is equivalent to those ligands as well as F1*S and A from serum. These results suggest that the oligosaccharide moieties of hAGP have negligible effects on the structural and ligand binding properties of hAGP. Thus, rF1 * S and C149R-A promise to be useful in studies on the drug binding sites of hAGP.
Introduction
Human a1-acid glycoprotein (hAGP), a member of the lipocalin family, consists of a polypeptide that contains 2 disulfide bonds and 5 carbohydrate chains, the latter of which account for about 45% of the total mass of the 40 kD protein. 1, 2) hAGP is a major binding protein for basic drugs in plasma, [3] [4] [5] and regulates their tissue distribution.
Indeed, transgenic mice expressing excess AGP administered saquinavir, a HIV protease inhibitor, showed low clearance and distribution volume compared to control mice. 6) In leukemia patients, serum concentration of imatinib, a tyrosine kinase inhibitor, displayed a positive correlation to that of hAGP. 7) Additionally, the large animal species difference in the pharmacokinetics/pharmacodynamics of 7-hydroxystaurosporine (UCN-01), an anticancer drug, was partially explained by the high affinity binding of UCN-01 to hAGP. 8) Most individuals produce two variants of hAGP (F1 * S and A), which have selectivity on drug binding. 9, 10) However, mechanistic aspects and detailed information on the binding sites of hAGP remain unclear because the 3D structure of hAGP has been determined only recently. 11) Generally, the 3D structure of a protein can be revealed by X-ray crystallographic analysis or nuclear magnetic resonance (NMR) spectral methods. Data obtained by such methods are useful for clarifying functional sites on a protein, such as ligand-binding sites. For such methods, it is important that the expressed protein molecules are homogeneous. In most cases of glycoproteins, the attached glycans cause heterogeneity in the molecule. This is especially true in the case of hAGP since it is the most heavily glycosylated protein found in plasma. Therefore, E. coli is frequently used as a host for the production of foreign proteins, because E. coli does not produce proteins that contain glycan chains. However, many eukaryotic proteins, especially fulllength proteins, are produced in E. coli in the form of insoluble aggregates (inclusion bodies). Whereas the formation of inclusion bodies can offer the advantage of easy purification, the possibility that a protein solubilized using reagents that promote refolding may not have the native protein conformation cannot be excluded. In some cases, the formation of inclusion bodies is thought to be due to the lack of proper polypeptide folding. 12, 13) One of the factors that affect the misfolding of eukaryotic proteins in E. coli is the fact that the redox state in E. coli is different from eukaryotic cells. Such an environment in E. coli frequently generates the formation of inappropriate disulfide bonds. Yasukawa et al. recently reported that many foreign proteins could be obtained in soluble fraction using a co-expression system with thioredoxin in E. coli. 14) This finding suggests that promoting the formation of disulfide bonds in E. coli leads to the appropriate folding of a protein molecule.
Last year, Sch äonfeld et al., for the first time, reported on the 3D structure of recombinant F1*S (rF1*S) without a ligand using rF1*S obtained from E. coli.
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This model provides useful information on the structure of this variant, such as the overall shape of the molecule and the location of drug binding sites. However, a 3D structural analysis for both F1S and A variant-drug complex is necessary to demonstrate the precise mechanism of the drug binding mode and to identify the precise amino acid residues that are involved in drug binding.
When a protein possesses free cystein residues (Cys), it is possible to induce heterogeneity, which causes difficulties in an X-ray crystallographic analysis. To avoid such Cys-derived heterogeneity, Cys residues are often replaced with other amino acids in X-ray crystallographic studies. In the case of hAGP, the A variant possesses only a free Cys at position 149 (Cys149) which is also a potential source of heterogeneity.
Glycans of glycoproteins generally play significant roles in the structural and/or functional properties of the glycoprotein molecule. Whereas hAGP is one of the most glycosylated proteins, the roles of oligosaccharide moieties of hAGP on structural and ligand binding properties are not well understood at present. Unfortunately, the 3D structure mode of rF1*S proposed by Sch äonfeld and co-workers did not take into account the effects of glycans on the structure and binding site of hAGP. 11) Change in structural properties of hAGP can affect the drug binding property. Therefore, information on an effects of glycans on structural property of hAGP can be helpful to evaluate the effects on it. It has been reported that oligosaccharide moieties have only a negligible effect on the structural properties of hAGP, 15, 16) but, to the contrary, it has also reported that this moiety does, in fact, has an effect. 17, 18) This discrepancy might be due to the difficulty in enzymatically preparing the oligosaccharidedeficient hAGP and to its tendency to undergo aggregation followed by a subsequent decrease in the solubility of oligosaccharide-deficient hAGP.
In the current study, we obtained recombinant F1*S and A variants (rF1*S and rA) in the soluble fraction from an E. coli system, using our newly constructed coexpression system with thioredoxin in the Origami B strain as a host of E. coli. Moreover, from evaluations of the structural and ligand-binding properties of the recombinant variants, we also investigated the roles of the oligosaccharide moiety of hAGP in such properties.
Materials and Methods
Materials: hAGP was purchased from Sigma Chemical Co. (St. Louis, MO). The pT-Trx vector was a gift from Dr. Shunsuke Ishii of the laboratory of molecular genetics, RIKEN Tsukuba Institute, Japan. The pET expression Kit 3 and Origami B (DE3) were purchased from Novagen (Darmstadt, Germany). Restriction enzymes, the DNA ligation kit and the DNA polymerase Premix Taq } (EX Taq version) were obtained from Takara Biotechnology (Kyoto, Japan). The DNA sequencing kit was obtained from Perkin-Elmer Applied Biosystems (Tokyo, Japan). Isopropyl-b-D-thiogalactopyranoside (IPTG) was purchased from Promega (Madison, USA). Propranolol was purchased from Wako Pure Chemical Industries (Osaka, Japan). Dipyridamole was purchased from Dojindo Lab. (Kumamoto, Japan). HiTrap Chelating HP column, Q-XL column and Sephadex G-100 were purchased from Amersham Biosciences Co. (Piscataway, USA). All other chemicals and solvents were of analytical grade.
Separation of hAGP genetic variants: The hAGP genetic variants were separated using the method of Herve et al.
10)
An iminodiacetate (IDA) Sepharose gel loaded with copper (II) ions and equilibrated in buffer 1 (20 mM sodium phosphate buffer, pH 7.0, containing 0.5 M sodium chloride) was packed into a column (2.0°A
¿30.0 cm L). Commercial hAGP (70 mg dissolved in 1.0 ml of buffer) was applied to the column at a flow rate of 1.0 ml/min. Fractions (10 ml) were collected, and their respective absorbance values were determined spectrometrically at 280 nm. As soon as variant A had been eluted, elution buffer 2 (buffer 1 plus 20 mM imidazole) was applied to the column to remove the bound F1*S. The peak fractions of each eluent were collected, dialyzed against deionized water, and lyophilized. The purities of the isolated hAGP preparations were determined by isoelectric focusing (IEF) followed by incubation at 37 9 C for 24 h with 1 U of neuraminidase.
Construction of rF1*S and rA expression vector: For the expression of rF1 * S and rA, the pET-3c vector, frequently used as an expression system in E. coli was used (Fig. 1) . cDNA of F1*S variant was a gift from Kyowa Hakko Co., Ltd. (Tokyo, Japan). The cDNA of the A variant was prepared according to our previous method. 19) A DNA fragment encoding F1 * S or A containing a His-tag (His x 6) was amplified by PCR respectively using each template and the following oligonucleotide primers: 5?-GGTCATATGCAGATCCCATTGTGTGCCA-ACCTAGTACCGG-3 (5? NdeI) and 5?-GGTGGATCCTC-ACTAGTGGTGGTGGTGGTGGTGGGATTCCCCCTCC-TCCTGTTTCC-3 (3? BamHI), and inserted into restriction enzyme sites, NdeI and BamH1, in a multicloning site on this vector.
Introduction of mutations into the A coding region: Site-directed mutagensis was performed to replace cystein with arginine at position 149 on A variant using Quickchange XL Site-Directed Mutagenesis Kit (Qiagen). The Mutagenic primer synthesized (underlined letters indicate mismatches) was 5?-CTCGACTGCTTGC GCATTCCCAGGTCA-3?. The mutation was confirmed by DNA sequencing of the entire A coding region using the dideoxy chain termination method using a Perkin-Elmer ABI Prism 310 Genetic Analyzer.
Expression of rF1*S, rA and C149R-A in E. coli (Origami B (DE3) strains): A pET-3c vector inserted cDNA of F1*S or A (pET-3c/F1*S or A) was transformed in the Origami B (DE3) strain that had been pre-transformed with pT-Trx. After culturing this transformant in LB medium Containing 2% glucose, 50 mg/mL ampicillin and 25 mg/mL chloramphenicol at 309 C, a 20 ml aliquot of the medium was cultured for 18 hr in 2×YT medium (1 L) including 2% glucose and 50 mg/mL ampicillin. After reaching an appropriate OD value at 600 nm (OD600＝0.5), rAGP expression was induced for 3 hr in the presence of 0.1 mM IPTG. After centrifugation (3,000 g, 15 min, 49 C), the pellet was suspended in 20 mM This-HCl buffer (pH 8.0), 50 mM NaCl, 20 mM imidazole and 0.1% CHAPS, and then sonicated. After centrifugation (15,000 g, 20 min, 49 C), the soluble and insoluble proteins were recovered in supernatant and pellet, respectively. The supernatant was loaded on to a HiTrap Chelating HP column. The target protein was eluted with 20 mM Tris-HCl (pH 8.0), 50 mM NaCl, 100 mM imidazole and 0.1% CHAPS. The eluate was then loaded onto a HiTrap Q-XL column. The protein was then eluted with 20 mM Tris-HCl (pH 8.0) and 0.1% CHAPS with a linear gradient of 0-1.0 M NaCl. Finally the eluate was loaded onto a Sephadex G100 column and eluted with 20 mM Tris-HCl (pH 7.4) containing 50 mM NaCl.
Western blot analysis: After measurement of protein content using a BCA protein assay reagent (Pierce, Rockford, IL), 2 mg of each sample were mixed in a loading buffer (2% SDS, 333 mM Tris-HCl (pH 6.8), 10% glycerol, 100 mM DTT) and heated at 1009 C for 3 min. The samples were separated by 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Immobilon-P; Millipore, Bedford, MA) by semi-dry electroblotting. The blots were blocked for 1 hr at room temperature with 5% ECL advance blocking agents (GE Healthcare Biosciences Corp., Piscataway, NJ) in PBS containing 0.05% Tween 20 (PBS-T). The blots were washed once with PBS-T and then incubated for 1 hr at room temperature with a primary antibody specific for hAGP rabbit polyclonal antibody (prepared in our lab) in PBS-T. The blots were washed 3 times with PBS-T and incubated with a secondary antibody (horseradish peroxidase-linked anti-rabbiti IgG (Invitrogen, Eugene, OR)) for 1 hr at room temperature. The blots were washed 3 times with PBS-T and the immunoblots were visualized using an ECL system (ECL Advance Western Blotting Detection Kit; GE Healthcare Bio-sciences Corp.) with LAS-4000EPUVmini (Fujifilm, Tokyo, Japan).
Measurement of far-UV CD spectra: CD spectra were measured using a Jasco Model J-720 spectropolarimeter at 259 C. The data are expressed as mean residue ellipticity, [u] . The protein concentration was 5 mM for the far-UV CD measurement made in 20 mM Tris-HCl buffer (pH 7.4). One mm cells were used in this measurement.
Measurement of fluorescence spectra: Fluorescence spectra were obtained using a Jasco FP-770 fluorometer (Tokyo, Japan). For measurement of intrinsic Trp fluorescence, AGP was dissolved at 5 mM in Tris-HCl buffer (pH 7.4), and the emission was monitored from 300 nm to 400 nm at an excitation wavelength of 295 nm.
Measurement of binding percentage (%) of propranolol and disopyramide: Bindings of drugs to AGPs (propranolol to rF1*S and serum derived F1*S (sF1*S) and disopyramide to C149R rA and serum derived A (sA)) were determined by the ultrafiltration method. AGPs and the drug were prepared in 4 mM in Tris-HCl buffer (pH 7.4). A 4 mM aliquot of AGPs solution containing 4 mM of each drug was incubated for 10 min on ice, and then centrifuged for 40 min at 2,000×g at 49 C. After centrifugation, filtrate concentrations were analyzed by HPLC to determine the fluorescence of propranolol (excitation: 295 nm and emission: 340 nm) or UV absorbance of disopyramide (260 nm). The HPLC system consisted of a Hitachi 655A-11 pump and Hitachi L-7480 fluorescence monitor for propranolol or Hitachi 655A variable-wavelength UV monitor for disopyramide. Lichrosorb RP-18 (Cica Merk, Tokyo, Japan) was used as the stationary phase. The mobile phase consisted of acetonitrile/0.02M potassium phosphate buffer (60:40, v/v) for propranolol, and acetonitrile/0.03M potassium phosphate buffer (72:28, v/v).
Data analysis: Data are shown as means±SD for the indicated number of experiments. The overall differences between groups were determined by one-way analysis of variance (ANOVA). A probability value of pº0.05 was considered statistically significant.
Results and Discussion
Expression of rF1*S and rA in E. coli (Origami B (DE3)): The pET system was used for the expression of recombinant hAGPs in E. coli. In this system, recombinant protein cloned downstream of the T7 promoter in the pET vector can be expressed by T7 polymerase. Yasukawa et al. previously reported that the solubility of foreign proteins is improved dramatically by the co-expression of thioredoxin. 14) In addition, the Origami B (DE3) strain, being deficient in thioredoxin and glutathione reductase, was used as a host to maintain the oxidation state of thioredoxin and glutathione. As shown in Figures 2A and 2B , rF1*S and rA was obtained in the soluble fraction in the E. coli lysate. These results indicate that the appropriate formation of disulfide bonds is important for the solubility of rF1*S and rA in E. coli and their proper folding.
After purification steps using several types of chromatography, single bands of rF1*S and rA were observed on SDS-PAGE under reducing conditions (Fig. 3A) , respectively. In addition, under non-reducing conditions (Fig. 3B) , a single band of F1*S also was observed. However, in the case of rA under the same conditions, several bands were observed. The results of western blotting showed that these bands included rA or molecules derived from rA (Fig. 3C) . Such heterogeneity was thought due to the higher reactivity of cystein residues in rA than that in rF1*S. Indeed, rA has a free cystein residue at 149 (C149), but rF1*S does not. Thus, the reactivity of C149 in rA may become higher and then enter into disulfide bond formation between rA variants or rA and other proteins, because the current oxidative con- ditions in E. coli are amenable to the formation of disulfide bonds. Therefore, we prepared a mutant, C149R-A in which Cys is replaced with Arg in rA, because arginine is the residue of F1*S at position 149. Such a replacement of Cys with other amino acids is typically performed in 3D structural analysis by X-ray crystallographic analysis, when Cys in a protein causes heterogeneity.
As shown at Figure 4 , a single band of C149R-A was observed under both reducing and non-reducing conditions. This suggests that C149R-A has homogeneity similar to that of F1 * S and may be used in an X-ray crystallographic analysis.
Structural properties of rF1*S and rA: The conformational structures of rF1*S and C149R-A were characterized by far-UV CD and intrinsic Trp fluorescence spectra at pH 7.4 and the results were compared with sF1*S and sA, respectively. In addition to sF1*S and sA, the far-UV CD spectra of rF1*S and C149R-A showed a minimum at 218 nm, a typical feature of a protein with an abundant b-sheet structure (Fig. 5) . The intrinsic Trp fluorescence spectra of rF1 * S and C149R-A were also similar to those of sF1*S and sA, respectively (Fig. 6) . These results suggest that most conformational structures of sF1*S and sA are preserved in rF1*S and C149R-A, respectively and that glycans chains have little effect on the structural properties of hAGP.
Ligand-binding properties of rF1*S and rA: To date, several groups have reported that glycan chains of AGP may affect its drug binding properties, 17, 18) while most other reports indicate that these chains are not significantly involved in the drug binding processes of hAGP. 15, 16) Such a discrepancy might be due to differences in the degree of oligosaccharide deficiencies in the hAGP used in binding experiments. In any case, these studies were carried out using samples in which the sugar residues were only partially removed, either chemically or enzymatically, because in the case of hAGP, the structures of the glycan chains are complex, thus making it difficult to prepare completely oligosaccharide-deficient hAGP by general procedures, such as treatment with glycopeptidase F. Thus, the expression system in E. coli constructed in this study permitted us, for the first time, to precisely reveal the effects of oligosaccharide moieties on the structural conformation and ligand binding properties of hAGP.
To investigate the binding capacity of rF1 * S, the percentages of bound propranolol were estimated using the ultrafiltration method (Fig. 7A) . Propranolol binds both variants equivalently, 10) and this drug is also well known to bind a primary binding site of F1*S variant with high affinity. 3) No significant difference between the recombinant and serum derived F1*S was observed. In addition, the binding of disopyramide to C149R-A and sA was estimated using an ultrafiltration technique because a selective binding of disopyramide to the A variant has been reported. 10) Therefore, this drug is very useful to evaluate the binding capacity of A variant. As expected, the percentage of bound disopyramide was very close between both proteins (Fig. 7B) . These data indicate that the ligand binding capacities of rF1*S and C149R-A are similar or equivalent to those of sF1*S and sA.
Based on the present data, we conclude that the oligosaccharide moieties may not play important roles in either the drug binding process or conformational structures of both variants of hAGP. In the future, crystal structures of rF1*S and C149R-A with or without a ligand will provide additional information on the contribution of glycan chains to the structural and functional properties of hAGP. In addition, a comparison of the 3D structure of the ligand bound form of F1*S and C149R-A may clarify the mechanism of drug binding selectivity between the hAGP variants. Moreover, there are some reports on the chiral selectivity of variants. [20] [21] [22] Therefore, more information on chiral selectivity may be helpful to speculate conformational similarity of the binding pocket, which is not easily detected by CD spectrum measurement or blotting using polyclonal antibody.
In summary, we successfully constructed an expression system for both rF1*S and C149R-A variants in the soluble fraction from E. coli, which resulted in the production of proteins without any glycan chains using a newly constructed co-expression system with thioredoxin in the Origami B strain as a host of E. coli. The results obtained from structural and binding experiments clearly show that rF1*S and C149R-A exhibit similar structural and binding properties and that these properties are similar to those of the serum derived hAGP variants. These results suggest that the oligosaccharide moieties and Cys149 have negligible effect on the structural and drugbinding properties of hAGP. Thus, rF1*S and C149R-A, produced via the current expression system in E. coli promise to be useful for revealing the 3D structure and drug binding sites of hAGP by X-ray crystallographic analysis. The X-ray crystallographic analysis of the drug-C149R-A complex is currently underway at these laboratories.
